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Abstract
Background: Despite ongoing findings on the relationship between elevated levels of alanine and aspartate
aminotransferases (ALT and AST) and metabolic syndrome (MetS), this association in diabetic patients without a
known cause for liver enzymes elevation other than diabetes, per se, remains unclear. In this study, we aimed to
assess the relationship between circulating liver enzymes and MetS in a relatively large sample of patients with
diabetes.
Methods: A total of 670 diabetic patients, without known causes of hepatocellular injury, were enrolled. Patients
with ultrasonographic signs of fatty liver disease were not included. Fasting blood samples were obtained and
biochemical characteristics were measured. MetS was defined according to the international diabetes federation
criteria.
Results: Serum ALT and AST were significantly higher in patients with MetS (p < 0.001). High waist circumference
and low HDL-cholesterol were significantly associated with elevated ALT (OR = 2.56 and 2.0, respectively) and AST
(OR = 2.23 and 2.21, respectively). ALT and AST were significantly associated with MetS (OR = 2.17 and 2.31,
respectively). These associations remained significant after multiple adjustments for age, sex, BMI, diabetes duration,
HbA1c and medications. There was a significant (p < 0.01) positive association between the number of the MetS
features and the level of ALT or AST.
Conclusion: In diabetic patients without ultrasonographic evidence of fatty liver, elevated aminotransferases are
independently associated with MetS. Despite negative ultrasound results in diabetic patients with MetS, the serum
level of liver aminotransferases may be elevated and should be more thoroughly monitored.
Introduction
Insulin insensitivity is a known cause of liver damage [1].
Elevation of circulating liver enzymes including aspartate
aminotransferase (AST), alanine aminotransferase (ALT),
and alkaline phosphatase (ALP) is suggestive of hepato-
cellular injury [2-5]. There is increasing evidence that
ALT is significantly and independently associated with
type 2 diabetes mellitus [6-8], however not all of the stu-
dies support this finding [9].
In recent years, nonalcoholic fatty liver disease
(NAFLD), as a novel component of insulin resistance and
metabolic syndrome (MetS), has drawn the attention of
many researchers. NAFLD encompasses a wide spectrum
of liver diseases ranging from simple benign steatosis to
steatohepatitis, fibrosis, and cirrhosis [1]. This condition
which is associated with long-standing elevations in liver
enzymes [10,11], is related to higher risk of adverse cardi-
ovascular events, oxidative stress, endothelial dysfunc-
tion, and MetS [12].
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NAFLD and MetS [13], the relationship between ele-
vated liver enzymes and MetS in diabetic patients with-
out a known cause for liver enzymes elevation other
than diabetes, per se, remains unclear. In particular,
while most of the studies describe the association
between MetS and elevated liver aminotransferases via
the NAFLD mechanism [14]; it is not clear what extent
of liver steatosis is sufficient to mediate the association
between liver enzymes and MetS in diabetes. To best of
our knowledge, no evidence is available regarding the
association between MetS and serum aminotransferases
in patients with mild stages of liver steatosis. To deter-
mine subjects with mild liver steatosis from those with
advanced stages, ultrasonography is an appropriate
screening tool. Ultrasonography with the sensitivity of
60-89 percent and specificity of 66-93 percent in detect-
ing steatosis is proved as a good tool for detection of
clinically significant fatty infiltrations, in epidemiologic
studies [15]. It is reported that individuals with negative
fatty liver changes in ultrasonography have hepatic fat
<30% [16].
Of note, there is limited evidence regarding the pat-
tern of abnormality in liver enzymes in diabetic patients
with and without MetS. In this study, we aimed to
assess the relationship between circulating liver enzymes
and MetS in a relatively large sample of Iranian patients
with type 2 diabetes, after excluding patients with ultra-
sonographic signs of NAFLD or any other known causes
of hepatocellular injury.
Methods
Study population
The study population consisted of 670 diabetic subjects
who consecutively visited Vali-Asr hospital outpatient
diabetes clinic (Tehran, Iran) from June 2007 to Sep-
tember 2009. Diabetes was diagnosed according to
American Diabetes Association (ADA) criteria [17]. The
study population was divided into two groups of diabetic
patients with (n = 502) and without MetS (n = 168).
MetS was defined according to the IDF criteria using
the cutoffs we recently established for waist circumfer-
ence (WC) in Iranian adults [18]. Subjects with abdom-
inal obesity (WC > 90 cm for both men and women)
plus at least two of the risk factors from the IDF criteria
including high triglyceride levels (TG ≥ 150 mg/dL), low
HDL-cholesterol (HDL-C ≤ 40 mg/dL in men and ≤ 50
mg/dL in women), high blood pressure (systolic BP
≥ 130 mmHg, diastolic BP ≥ 85 mmHg or treatment of
previously diagnosed hypertension), and high fasting
plasma glucose level (FPG ≥ 100 mg/dL or treatment of
previously diagnosed diabetes) were considered to have
MetS. Since all of our patients were known cases of
diabetes, abdominal obesity plus at least one of the
above factors was sufficient to establish a clinical diag-
nosis of MetS in this study.
A thorough history was taken and physical examination
was performed by a trained physician for all patients.
None of our patients were on insulin or thiazolidinedione
treatment. Patients with a history of alcohol consump-
tion, as well as those with history of a known chronic
liver disease including autoimmune hepatitis, hemochro-
matosis, Wilson’s disease, primary biliary cirrhosis, and
sclerosing cholangitis were not included in the study. No
subject had history of taking medications that are com-
monly attributed to liver enzyme elevations (such as
methotrexate, tetracycline, amiodarone, high doses of
estrogen, tamoxifen, diclofenac, amoxicillin, valproic acid
or steroids). Abdominal ultrasonography for evaluation
of liver (Hitachi EUB 405 apparatus equipped with a con-
vex 3.5 MHz probe) was performed in patients, by a sin-
gle experienced radiologist (to avoid inter-operator
discordance) and those with evidence of fatty liver were
excluded. Biochemical evaluation including serum ALT
and AST was performed in all subjects. All patients with
elevated liver enzymes underwent serologic examination
for hepatitis B and C viruses, and those with positive
results were not included in the study. Auto antibodies
(antinuclear antibody and anti-smooth muscle antibody)
and biochemical features (including iron studies, cerulo-
plasmin, and urinary copper) were also measured in
patients with elevated liver enzymes and those with
abnormal results were not included.
The study was approved by the local ethics committee
of Tehran University of Medical Sciences. All subjects
were provided with written informed consent and the
study was conducted in accordance with Helsinki
declaration.
Data collection
Anthropometric data including age, sex, height, weight
and WC were collected. Height was measured with sub-
ject standing without shoes by a standard stadiometer
and the nearest one centimeter was recorded. Weight
was measured with subjects wearing only light clothing
standing on a digital scale; the nearest 0.5 kilogram was
recorded. WC was measured at the end of a normal
expiration, midway between the inferior margin of the
ribs and superior border of the iliac crest in a horizontal
plane, and was rounded to the nearest 0.1 cm, according
to the previously published literature [19]. Body mass
index (BMI; kg/m
2) was calculated according to the
Quetelet equation (weight in kilograms divided by
height in square meter) [20]. BP was measured on the
right arm with subject having relaxed for at least 5 min-
utes, via a standard sphygmomanometer of appropriate
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average of these two measurements was recorded for
systolic and diastolic BP.
Laboratory methods
Venous blood samples were collected following an over-
night 12-hours of fasting and HbA1c, TG, cholesterol
(Chol), HDL-C, low density lipoprotein-cholesterol
(LDL-C), fasting plasma glucose (FPG), AST, ALT and
ALP were measured. FPG measurement was carried out
using the glucose oxidase method. Chol, TG, LDL-C,
and HDL-C were determined using enzymatic methods.
Analyses of serum ALT, AST and ALP were performed
using enzymatic photometry. ALT level > 30 U/L in
women and > 40 U/L in men, AST level > 30 U/L in
women and > 36 U/L in men and ALP levels of greater
than 306 U/L in both women and men were considered
elevated according to the manufacturer’s instructions.
Serum ALT and AST were measured by the IFCC
(International Federation of Clinical Chemistry and
Laboratory Medicine) method (ALT intra-assay coeffi-
cient of variation [CV] = 3.7%, AST intra-assay CV =
2.5%). Serum ALP was measured using the DGKC
(Deutsche Gesellschaft für Klinische Chemie) method
(Intra-assay CV = 1.5%). These measurements were con-
ducted using commercial Parsazmun kits (Tehran, Iran)
and a Hitachi 704 automatic analyzer (Tokyo, Japan)
[21]. HbA1c was measured using the high performance
liquid chromatography method. For diagnosis of hepati-
tis B and C, antibodies to hepatitis C virus, hepatitis B
surface antigen, hepatitis B surface antibody, hepatitis B
core antibody, hepatitis B e antigen, and hepatitis B e
antibody were measured using commercially available
enzyme linked immunosorbent assay (ELISA) kits (DRG
Diagnostics GmbH, Germany).
Statistical analysis
All statistical analyses were performed using SPSS soft-
ware version 17.0 for windows (SPSS Inc. Chicago, IL,
USA). Continuous variables are expressed as mean ±
standard deviation. Independent sample t-test was used
to identify differences of continuous variables between
groups with and without MetS. Categorical variables
were compared using Chi square analysis. The degree of
association between continuous variables was assessed
via Pearson’s correlation coefficient (r). Logistic regres-
sion analysis was performed to assess the independent
correlations between different features of MetS, and
ALT or AST. General linear models were used to com-
pare the adjusted mean values of ALT or AST in
patients with different numbers of metabolic abnormal-
ities. P value < 0.05 was considered statistically
significant.
Results
A total of 670 diabetic patients without ultrasound evi-
dence of fatty liver, with the mean age of 54.12 ± 10.49
years (range: 18-80 years) were included in the study.
Females constitute 360 (53.7%) of the patients. The
mean and median of diabetes duration in the study
population was 5.84 ± 5.69 and 5.00 years, respectively.
The prevalence of MetS in the patients was 74.9%.
About 31.5% of the patients (n = 204) had elevated ami-
notransferases, 110 had only elevated ALT, 13 had only
elevated AST and the remaining 81 patients had both
elevated ALT and AST. Elevation in ALT or AST was
mild in all our patients (less than 2.5 times elevation
compared with upper limit of normal range).
As Table 1 summarizes, there were no significant dif-
ferences in the age, sex, diabetes duration, HbA1c, FPG,
LDL-C, Chol, and ALP levels in the patients with and
without MetS. However, BMI, WC, diastolic and systolic
BP, TG, HDL-C, AST and ALT levels were higher in
patients with MetS. Furthermore, there were no signifi-
cant differences between patients with and without
MetS with respect to use of oral anti-diabetic medica-
tions, lipid lowering or antihypertensive agents. Also
there were no significant association between elevated
ALT/AST and use of oral anti-diabetic medications (P =
0.589 and P = 0.224 for elevated ALT and elevated AST,
respectively), lipid lowering agents (P = 0.859 and P =
0.262, respectively) or anti-hypertensive medications
(P = 0.718 and 0.181, respectively). Both long term con-
trol of glycemic situation measured by HbA1c level, and
short term glycemic control quantified by FPG was simi-
lar in patients with and without elevated ALT (P = 0.20
and 0.69, respectively).
In univariate analysis, serum ALT level was signifi-
cantly (p < 0.05) correlated with AST (r = 0.758), age
(r = 0.196), diabetes duration (r = 0.149), WC (r =
0.200), TG (r = 0.159) and was negatively associated
with HDL-C (r = -0.165). No significant correlation was
observed between ALT and ALP level, BP (systolic or
diastolic), HbA1c, FPG, and LDL-C. Similar to ALT,
AST was significantly (p < 0.05) correlated with age (r =
0.129), diabetes duration (r = 0.123), WC (r = 0.188),
and was negatively associated with HDL-C (r = -0.137).
No significant correlation was observed between AST
and TG, ALP, BP (systolic or diastolic), HbA1c, FPG or
LDL-C.
As shown in Table 2, patients with elevated ALT had
significantly higher prevalence of impaired TG levels.
However, after adjustment for various confounding fac-
tors the significant association disappeared. In addition,
the prevalence of Low HDL-C and high WC was signifi-
cantly higher in patients with elevated ALT and remained
significant even after multiple adjustments (OR = 2.04,
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respectively). Elevated levels of AST had no significant
association with either high BP or high levels of serum
TG. Furthermore, although patients with elevated AST
had higher prevalence of low HDL-C and high WC, only
HDL-C remained significant after adjustment for age,
sex, BMI, diabetes duration, HbA1c, and various medica-
tions (OR = 2.13, 95% CI: 1.06-4.31). Both elevated ALT
a n dA S Th a das i g n i f i c a n t( p<0 . 0 1 )a s s o c i a t i o nw i t h
increase in the number of features of MetS (Figure 1).
Discussion
This study demonstrates that in a reasonably large sam-
ple of patients with diabetes, liver enzymes are signifi-
cantly higher in patients with MetS, in spite of similar
long and short-standing glycemic control indices and
similar diabetes duration. We also observed that ele-
vated liver enzymes are associated with age, diabetes
duration and features of MetS including serum HDL-C
level and WC. Oral anti-diabetic, anti-hypertensive, and
lipid lowering agents could minimally influence our
observed associations, since there was no significant dif-
ference between use of medication in patients with and
without MetS and also in patients with elevated and
normal liver enzymes.
There are very few studies assessing the association
between liver enzymes and MetS in patients with dia-
betes. Hickman et al (2007), on a sample of 189 patients
with diabetes, showed that MetS is associated with an
unexplained increase in ALT, despite similar glycemic
control in patients with and without MetS [22]. In this
study, liver enzymes other than ALT including AST and
ALP were not assessed. In another study by Forlani and
collegues (2008), it was shown that presence of MetS is a
significant predictor of raised ALT [23]. These studies
did not evaluate the presence of NAFLD in the partici-
pants. In the present study, for the first time, we excluded
cases with ultrasonographic signs of NAFLD, focusing on
Table 1 Clinical and laboratory characteristics of the study subjects with and without metabolic syndrome (MetS)
Variables Without MetS With MetS P value
N (%) 168 (26.6) 502 (74.9) -
Age (years) 53.39 ± 10.34 54.36 ± 10.54 0.300
Females (n, %) 101 (60.11) 259 (51.59) 0.054
Diabetes duration (years) 5.94 ± 6.35 5.81 ± 5.46 0.800
Body mass index (kg/m
2) 25.96 ± 3.48 30.78 ± 4.69 < 0.001*
Waist circumference (cm) 88.59 ± 8.43 102.94 ± 8.67 < 0.001*
Diastolic blood pressure (mmHg) 78.77 ± 7.28 81.56 ± 8.19 < 0.001*
Systolic blood pressure (mmHg) 122.50 ± 13.92 130.94 ± 17.34 < 0.001*
Anti hypertensive medications
a (n, %) 68 (40.50) 200 (39.84) 0.917
Anti-Diabetic Medications (n, %) 0.470
No medication 0 (0) 2 (0.01)
Glibenclamide 29 (17.8) 71 (14.1)
Metformin 34 (20.2) 123 (24.5)
Glibenclamide & Metformin 63 (37.5) 206 (41.0)
Lipid Lowering Agents (n, %) 0.189
No medication 103 (61.31) 271 (53.98)
Statins 53 (31.55) 174 (34.66)
Fibrates 4 (2.38) 30 (5.97)
Statins & Fibrates 8 (4.76) 22 (4.38)
HbA1c (%) 7.68 ± 1.92 8.03 ± 1.77 0.130
Fasting plasma glucose (mg/dL) 162.86 ± 58.13 166.49 ± 53.23 0.445
Triglycerides (mg/dL) 158.21 ± 90.03 213.01 ± 118.73 < 0.001*
HDL-C (mg/dL) 48.16 ± 11.26 44.23 ± 12.60 < 0.001*
LDL-C (mg/dL) 115.59 ± 37.77 111.73 ± 36.05 0.236
Total cholesterol (mg/dL) 195.08 ± 44.84 197.29 ± 45.34 0.583
Alanine aminotransferase (U/L) 27.30 ± 15.23 31.76 ± 18.74 0.006*
Aspartate aminotransferase (U/L) 21.53 ± 9.58 24.17 ± 13.84 0.007*
Alkaline phosphatase (U/L) 148.44 ± 92.83 151.95 ± 77.01 0.653
*P value < 0.05.
Variables are presented as mean ± standard deviation unless stated otherwise.
a Medication used for treatment of hypertension include angiotensin converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers and
beta blockers.
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known cause, except diabetes, per se. Our results showed
an independent association between MetS and mildly ele-
vated AST/ALT in diabetes patients without ultrasound
evidence of fatty liver disease. This can be due to a mild
underlying steatohepatitis, which is undetectable by
ultrasound. Our results can be interpreted in parallel
with the findings of the study by Mofrad et al (2003),
which showed that even low normal ALT values can be
associated with underlying steatohepatitis, especially in
diabetic patients [24].
The pathogenesis of liver damage in patients with dia-
betes is not thoroughly understood and most of our cur-
rent knowledge is related to the connection between
NAFLD and insulin resistance [14,25]. Hepatic insulin
resistance can play an important role in liver dysfunction
and elevation of liver enzymes [8,26]. Also, inflammatory
cytokines including tumor necrosis factor and interleukin
6 are proposed in pathogenesis of hepatocellular injury in
insulin resistance/MetS [14]. Increased levels of TG and
free fatty acids causes accumulation of TG in nonadipose
tissues including liver [27] which results in lipid peroxi-
dation. Subsequently, mitochondrial dysfunction caused
by formation of toxic metabolites and reactive oxygen
species induces cell apoptosis [14,25,28]. The association
between MetS and liver enzymes in our study shows that
in diabetes, MetS is possibly linked to undetectable mild
stage of NAFLD. This notifies clinicians to more thor-
oughly monitor serum aminotransferase in diabetic
patients, particularly when the diabetic patient has MetS
as well. NAFLD is a feature of MetS [29], and in diabetic
patients with MetS, regardless of negative ultrasound
results, NAFLD might be present and contribute to the
complex of different features of MetS.
This study had potential limitations: first, the cross-
sectional nature of this study precludes cause and effect
relationships. Therefore, further longitudinal studies are
paramount to investigate the role of liver enzymes as
risk factors of the MetS. Second, it should be noted that
liver biopsy is considered as the gold standard of diag-
nosis of NAFLD [30,31], however it is invasive, expen-
sive, and may bear potential risks [32]. There are some
imaging techniques for assessing hepatic fat content.
Table 2 Features of the metabolic syndrome in patients with and without elevated liver aminotransferases
Diabetic patients
Variables (n, %) without increased
ALT
(n = 479)
with increased
ALT
(n = 191)
Crude OR
(95% CI)
Adjusted OR
(95% CI)
High blood pressure 203 (42.4) 91 (47.6) 1.24 (0.88-1.73) 1.11 (0.68-1.80)
1
High triglycerides 286 (59.7) 135 (70.7) 1.63 (1.13-2.33)* 1.50 (0.91-2.48)
1
Low HDL-C 256 (53.4) 133 (69.6) 2.00 (1.40-2.58)*** 2.04 (1.24-3.38) **
1
High waist circumference 368 (26.8) 171 (89.5) 2.56 (1.53-4.26)*** 2.48 (1.20-5.11) *
1
MetS 341 (71.2) 161 (84.3) 2.17 (1.40-3.36)*** 2.08 (1.12-3.87) *
1
without increased
AST
(n = 576)
with increased
AST
(n = 94)
High blood pressure 249 (43.2) 45 (47.9) 1.21 (0.78-1.87) 1.05 (0.56-1.98)
2
High triglycerides 354 (61.4) 67 (71.3) 1.56 (0.97-2.51) 1.39 (0.71-2.73)
2
Low HDL-C 320 (55.6) 69 (73.4) 2.21 (1.36-3.59)** 2.13 (1.06-4.31) *
2
High waist circumference 405 (70.3) 84 (89.4) 2.23 (1.12-4.43)* 2.17 (0.89-5.31)
2
MetS 421 (73.1) 81 (86.2) 2.31 (1.25-4.27)** 2.23 (1.09-4.57) *
2
*P < 0.05, **P < 0.01, ***P < 0.001.
1Adjusted for age, sex, BMI, diabetes duration, HbA1c and medications (anti diabetic, lipid lowering or antihypertensive agents).
2Adjusted for age, sex, BMI, diabetes duration, HbA1c and medications (anti diabetic, lipid lowering or antihypertensive agents).
Figure 1 There was a significant (p < 0.01) association
between the number of the metabolic abnormalities and ALT
or AST, after adjustment for age, sex and BMI, HbA1c, diabetes
duration and medications.
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tatively detect macrovesicular steatosis of 30% and
more, however there are conflicting evidence on its
value in quantifying liver fat content [32]. Enhanced CT
is less valuable in assessing liver fat since contrast type,
injection rate, and timing can significantly influence the
liver to spleen attenuation difference for diagnosing fatty
liver [33,34]. Several studies have demonstrated an
appropriate correlation between severity of steatosis on
magnetic resonance imaging (MRI) and histologic biop-
sies [35-37]. Emerging imaging techniques such as dual
gradient echo MRI (DGE-MRI) and proton magnetic
resonance spectroscopy (
1H-MRS), are currently evalu-
ated for detecting hepatic steatosis. One study has
demonstrated DEG-MRI is highly accurate for evaluat-
ing moderate to severe hepatic steatosis (sensitivity and
specificity of greater than 90%) and fairly sensitive (sen-
sitivity = 76.7%) and specific (specificity = 87.1%) for
detection of all degrees of steatosis [38]. According to
our current knowledge, most studies have shown that
1H-MRS is the method of choice for detecting steatosis,
with a high correlation between the fat fraction esti-
mated by this method (r = 0.70 and 0.71) and histologic
evaluation [38-40]. Nevertheless, we believe that for the
purpose of this epidemiologic study, ultrasonography is
an appropriate screening tool for determining negative
or mild stages of fatty liver disease, with a reasonable
accuracy [15]. Our study provided significant insight to
our knowledge on the association between elevated liver
enzymes and MetS in diabetic patients with mild stages
of fatty liver, undetectable in ultrasound. An interesting
topic, which needs further attention in future studies, is
the significance of serum gamma-glutamyl transpepti-
dase (GTP) in diabetic patients, and its association with
MetS. It is interesting to compare GTP with AST or
ALT in prediction of MetS in a diabetes status.
In conclusion, we showed an independent association
b e t w e e ne l e v a t e dA L T / A S Ta n dM e t Si nd i a b e t i c
patients with undetectable mild stages of NAFLD.
Despite negative ultrasound results, the serum level of
liver aminotransferases mayb ee l e v a t e di nd i a b e t i c
patients with MetS and should be more thoroughly
monitored.
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